F
43
-8
MRO
55
3
HD
47
-5
USB
50
2
DVN
16
3
TXT
48
2
MRK
22
3
IBM
54
4
PX
75
5
NWL
44
-4
AZO
46
-3
NAVI
41
-3
AXP
66
2
SYF
85
2
MCO
73
3
DHI
48
3
IVZ
46
3
ZBH
60
-2
EQT
59
2
VFC
47
-5
F
43
-8
MRO
55
3
HD
47
-5
USB
50
2
DVN
16
3
TXT
48
2
MRK
22
3
IBM
54
4
PX
75
5
NWL
44
-4
AZO
46
-3
NAVI
41
-3
AXP
66
2
SYF
85
2
MCO
73
3
DHI
48
3
IVZ
46
3
ZBH
60
-2
EQT
59
2
VFC
47
-5
Financhill
Back

Akebia Therapeutics 10K Form

Buy
59

AKBA
Akebia Therapeutics

Last Price:
1.82
Seasonality Move:
42.93%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AKBA News And Ratings

See the #1 stock for the next 7 days that we like better than AKBA

AKBA Financial Statistics

Sales & Book Value

Annual Sales: $194.62M
Cash Flow: $-6.7M
Price / Cash Flow: 0
Annual Sales: $-0.24
Price / Book: 0

Profitability

EPS (TTM): -0.22680
Net Income (TTM): $-45.99M
Gross Margin: $120.47M
Return on Equity: 0%
Return on Assets: -20.36%

Akebia Therapeutics Earnings Forecast

Key Akebia Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for AKBA is 61.90%.
  • The Selling, General & Administrative Expenses for AKBA have been equal to 51.50% of Gross Profit Margin.
  • The Research & Development expenses have been 32.41% of Revenue.
  • The Interest Expense is -11.62% of Operating Income.
  • The Net Earning history of AKBA is -26.68% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Akebia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AKBA
CUSIP: 00972D
Website: akebia.com

Debt

Debt-to-Equity Ratio: -0.76
Current Ratio: 1.52
Quick Ratio: 1.01

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AKBA Technical Analysis vs Fundamental Analysis

Buy
59
Akebia Therapeutics (AKBA) is a Buy

Is Akebia Therapeutics a Buy or a Sell?